更正：高等人。RNF8与CDH1共表达预测三阴性乳腺癌放化疗的临床获益。2021年，，655。
Correction: Kao et al. RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. 2021, , 655.
作者信息
Kao Chieh-Ni, Moi Sin-Hua, Hou Ming-Feng, Luo Chi-Wen, Chen Fang-Ming, Pan Mei-Ren
机构信息
Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
出版信息
J Pers Med. 2022 Mar 15;12(3):466. doi: 10.3390/jpm12030466.
Abstract
The authors would like to make corrections to a recently published paper [...].
摘要
作者们想要对最近发表的一篇论文[...]进行更正。
相似文献
1
Correction: Kao et al. RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. 2021, , 655.更正：高等人。RNF8与CDH1共表达预测三阴性乳腺癌放化疗的临床获益。2021年，，655。
J Pers Med. 2022 Mar 15;12(3):466. doi: 10.3390/jpm12030466.
2
RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer.RNF8与CDH1共表达可预测三阴性乳腺癌放化疗的临床获益
J Pers Med. 2021 Jul 13;11(7):655. doi: 10.3390/jpm11070655.
3
Correction: Hasegawa et al. Impacts of Interaction of Mental Condition and Quality of Life between Donors and Recipients at Decision-Making of Preemptive and Post-Dialysis Living-Donor Kidney Transplantation. 2021, , 414.更正：长谷川等人。在优先和透析后活体供肾移植决策中供体和受体心理状况与生活质量相互作用的影响。2021年， ，414。
J Pers Med. 2022 Dec 9;12(12):2036. doi: 10.3390/jpm12122036.
4
Correction: Brauner et al. Dental Management of Maxillofacial Ballistic Trauma. 2022, , 934.
J Pers Med. 2023 Mar 17;13(3):535. doi: 10.3390/jpm13030535.
5
Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. 2022, , 1174.更正：贝努奇等人。预测非药物转换后疗效丧失：依那西普转换为SB4的患者及初治风湿性疾病患者中循环肿瘤坏死因子-α水平与SB4之间的相关性。2022年，，1174。
J Pers Med. 2023 Jan 18;13(2):168. doi: 10.3390/jpm13020168.
6
Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. 2023, , 553.pT3N0M0 期胃癌切除患者辅助化疗的应用原理。对 Chen 等人的评论。病理淋巴结阴性的 T3 期胃癌的预后因素及辅助化疗的作用。2023 年，，553。
J Pers Med. 2023 Jun 9;13(6):974. doi: 10.3390/jpm13060974.
7
Reply to Graziosi et al. Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on "Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. 2023, , 553".对格拉齐奥西等人的回复。pT3N0M0期胃癌切除患者辅助化疗的应用原理。评“陈等人。病理淋巴结阴性T3期胃癌的预后因素及辅助化疗的作用。2023年，，553”
J Pers Med. 2023 Jun 13;13(6):988. doi: 10.3390/jpm13060988.
8
Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. 2017, , 19.更正：安东尼乌，M.；等人。生存结局的固定和自适应并行亚组特定设计：功效与样本量。2017年，，19。
J Pers Med. 2018 May 7;8(2):18. doi: 10.3390/jpm8020018.
9
The ubiquitin ligase RNF8 regulates Rho GTPases and promotes cytoskeletal changes and motility in triple-negative breast cancer cells.泛素连接酶 RNF8 调节 Rho GTPases，并促进三阴性乳腺癌细胞中的细胞骨架变化和迁移。
FEBS Lett. 2021 Jan;595(2):241-252. doi: 10.1002/1873-3468.13999. Epub 2020 Dec 5.
10
Correction: Rivera-Picón et al. Factors Associated with Adherence to Treatment in Patients with HIV and Diabetes Mellitus. 2023, , 269.更正：里维拉 - 皮孔等人。与艾滋病毒和糖尿病患者治疗依从性相关的因素。2023年，，269。 （注：原文中“2023, , 269”表述似乎不完整或有误，翻译时保留了原文状态）
J Pers Med. 2023 Jul 31;13(8):1215. doi: 10.3390/jpm13081215.
本文引用的文献
1
RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer.RNF8与CDH1共表达可预测三阴性乳腺癌放化疗的临床获益
J Pers Med. 2021 Jul 13;11(7):655. doi: 10.3390/jpm11070655.
Zotero 插件